Biomax provides AI-based semantic search platform AILANI for COVID-19 free of charge and supports international efforts to fight coronavirus epidemics

(PresseBox) ( Planegg, )
The bioinformatics company Biomax, headquartered in Planegg, Germany, makes its semantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful search for drugs and suitable vaccines against COVID-19 infections.

Biomax experts have pre-configured AILANI for the specific needs of researchers in the field of COVID-19 and integrated publicly available literature, data and knowledge. Using AILANI scientists get faster insight in existing knowledge, discover previously unknown associations and are able to take better research decisions. The new search platform is accessible at

Biomax also supports international efforts to collect knowledge with a special text mining system. In this context Biomax is partner of PREPARE, a platform for European Preparedness against (Re-)Emerging Epidemics, and member of the COVID-19 Disease Map Community, a European program that has been set up to share resources and best practices to develop a disease map for COVID-19 and SARS-CoV-2.

Biomax's expertise in electronic case reporting (eCRF) and the established data integration system BioXM additionally enables the design of an open, comprehensive information network for the collection, management and analysis of data on the COVID-19 epidemic, clinical disease progression or rehabilitation, to help physicians find the best treatment for their individual patients.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to